New Delhi: Bioneemtec India Private Limited, Chennai, has received support from the Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, for its project titled “Manufacturing of Minoxidil, Tranexamic Acid, Dequalinium Chloride, their Intermediates and Drug Liposomes.”
The initiative aims to commercialize indigenous green chemistry technologies for the production of critical pharmaceutical ingredients and advanced drug delivery systems, contributing to import substitution, sustainable manufacturing, and healthcare security.
The support extended to Bioneemtec comes at a time when India continues to strengthen its position as a global pharmaceutical manufacturing hub.
The project seeks to establish advanced manufacturing capabilities for pharmaceutical intermediates, Active Pharmaceutical Ingredients (APIs), and innovative drug delivery systems through a combination of batch and continuous-flow chemistry technologies.
Through the adoption of modern process technologies, Bioneemtec aims to enhance production efficiency, improve product quality, increase operational safety, and promote environmental sustainability.
Also Read: InnoVent-27: Tata Technologies Invites Engineering Students to Build AI at the Edge Solutions
The initiative is also expected to reduce the pharmaceutical sector’s dependence on imported intermediates and strengthen domestic manufacturing capabilities.
A significant aspect of the project is the commercialization of an indigenous manufacturing process for Tranexamic Acid, a widely used therapeutic molecule for managing bleeding disorders.
Developed through a cost-effective and environmentally responsible synthesis route, the technology is designed to deliver high-purity products while reducing waste generation and simplifying manufacturing processes.
In addition to Tranexamic Acid, Bioneemtec will support the domestic production of Minoxidil and Dequalinium Chloride, along with their key intermediates.
The initiative is expected to strengthen India’s pharmaceutical value chain by reducing reliance on imported raw materials and critical pharmaceutical ingredients.
Adding a strong innovation component to the project, Bioneemtec has developed proprietary Drug Liposome APIs based on advanced nanotechnology platforms.
These liposomal formulations are being developed for therapeutic applications, including breast cancer and skin cancer management. According to the company, the formulations have demonstrated promising results with controlled nanoparticle characteristics.
The company has also initiated intellectual property protection measures for its liposomal technology, laying the groundwork for future advancements in targeted drug delivery systems and next-generation pharmaceutical therapies.
Speaking on the occasion, Rajesh Kumar Pathak, Secretary, TDB, stated, “The future of pharmaceutical manufacturing lies in sustainable, technology-driven production systems that combine quality, efficiency, and environmental responsibility.
Indigenous development of advanced APIs, critical intermediates, and novel drug delivery platforms will be instrumental in strengthening India’s position as a global pharmaceutical manufacturing hub.
TDB is committed to supporting such innovative enterprises that are creating high-value technologies while contributing to import substitution and healthcare security.”
Also Read: Innefu Labs Secures $30 Million Series B Investment from Panthera Growth Partners
Expressing gratitude for the support, the leadership of Bioneemtec India Private Limited stated that the project will enable the company to scale up the commercialization of its green chemistry-based manufacturing technologies and advanced pharmaceutical products.
The company further noted that the support will accelerate the development of indigenous capabilities in API manufacturing and next-generation therapeutic formulations while creating opportunities in both domestic and international markets.
The initiative reflects the growing emphasis on sustainable pharmaceutical manufacturing, indigenous technology development, and advanced drug delivery innovations.
With support from TDB-DST, Bioneemtec is expected to strengthen India’s pharmaceutical ecosystem through the commercialization of green chemistry-based technologies, advanced APIs, pharmaceutical intermediates, and liposomal drug delivery solutions.
